Replies to post #6687 on Halozyme Therapeutics Inc (HALO)

[maumar]

Yes, I think it should be a good Q. Phesgo's growth hopefully offsets the decline in sales for Herceptin and Mabthera. The good and bad news is that Darzalex FasPro may account for 80% of the royalties. We just have to hope that there is concrete progress in the phase 3 trials. And we also need at least another new deal for the stock to get to new highs imho.